First-in-class host-targeting antiviral therapies against severe respiratory viral infections, including COVID-19 and influenza.
Great potential against a wide range of respiratory viruses due to antiviral and immunomodulating activity of ATRIVA’s lead product ATR-002. Phase II RESPIRE study to evaluate efficacy in hospitalized COVID-19 patients started in early 2021 (NCT04776044). Start of Phase II in influenza is planned later in 2021.
In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.
